HemoShear to Present Cardiovascular Drug Discovery Insights at Leading Scientific Conference
CHARLOTTESVILLE, Va., April 25, 2013 /PRNewswire/ -- HemoShear LLC, a leading developer of human-relevant systems for drug discovery and development, will present cardiovascular drug discovery insights from three separate studies at the annual American Heart Association's Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) conference to be held in Lake Buena Vista, Florida on May 1-3, 2013. ATVB is the world's leading scientific conference focusing on advancement of scientific research in vascular diseases.
HemoShear's studies provide human-relevant data and models that are essential to de-risking development of new drug treatments and providing a flow of qualified new drug candidates. The studies that HemoShear will present at ATVB demonstrate several important findings for drug R&D decision-making: that certain types of HDL, the supposedly "good" cholesterol, can cause arterial inflammation; that HemoShear has created a model of atrial fibrillation-induced thrombosis for new drug discovery; and that GLP-1 drug metabolites are a promising strategy for improving vascular health.
Each study was funded by, and is being presented in collaboration with, major biopharmaceutical companies Merck, Lilly and Amgen in the course of supporting their drug discovery and development activities. The studies were conducted with HemoShear's unique translational science that provides insights into disease targets and disease conditions that are not obtainable by any other science.
DATE: May 1, 2013
PRESENTATION #: 133
TITLE: Hemodynamic Environment-dependent Effects of Human HDL and oxHDL on Vessel Wall Inflammation.
AUTHORS: Jim Turk, Charles W. Qualls, Jr. - Amgen, Inc.
Ryan Feaver, Sol Collado, Sandi Walton, Nathan Day, David Manka, Brian Wamhoff, Brett Blackman - HemoShear LLC
DATE: May 2, 2013
PRESENTATION #: 73
TITLE: Atrial Fibrillation-induced Changes in Left Atrial Hemodynamics Directly Impact the Thrombotic Potential of Human Primary Endothelial Cell Cultures.
AUTHORS: Z Chen, Y Xu, L Kong, ML Ogletree - Merck & Co, Merck Research Labs
BR Wamhoff, MB Simmers, B Cole, AW Pryor, DJ Berry, N Day, BR Blackman - HemoShear, LLC
DATE: MAY 2, 2013
PRESENTATION #: 310
TITLE: GLP-1 Cleavage Product (9-36)-NH2 Exerts Pro-Survival Effects on Smooth Muscle Cells in Advanced Inflammatory Hemodynamic Conditions.
AUTHORS: Mark Rekhter, Jorge Alsina-Fernandez , Mark Kowala - Lilly Research Laboratories
Ryan Feaver, Sandi Walton, Nathan Day, Brian Wamhoff, Brett Blackman - HemoShear LLC
About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health. For more information, please visit www.hemoshear.com.
SOURCE HemoShear LLC